Humanized anti-emap ii antibody and use thereof
AssigneesHee Koung Kim, L&K Biomed Co., Ltd., Cell & Bio Co., Ltd.
InventorKang-Jun Yoon
Life of this patent
Estimating the term…
Abstract
The present invention provides a humanized anti-EMAP II antibody, the use of the humanized antibody, and pharmaceutical compositions containing the humanized antibody. The humanized anti-EMAP II antibody shows reduced immunogenicity and increased half-life while having similar or improved antigen binding capacity compared to the parent monoclonal antibody. Thus, the humanized anti-EMAP II antibody of the present invention can be more effectively used as a diagnostic reagent for EMAP II and a therapeutic agent for diseases that are mediated by EMAP II.
Claims19
A humanized anti-EMAPII (endothelial monocyte activating polypeptide II) antibody, comprising:
- (i) a light-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO:
- 12 to SEQ ID NO:
- 18;
- and
- (ii) a heavy-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO:
- 20 to SEQ ID NO:
- 26.
A nucleic acid molecule encoding a light-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO:
- 12 to SEQ ID NO:
- 18.
A nucleic acid molecule encoding a heavy-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO:
- 20 to SEQ ID NO:
- 26.
A recombinant vector, comprising nucleic acid molecules encoding a light-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO:
- 12 to SEQ ID NO:
- 18 and/or heavy-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO:
- 20 to SEQ ID NO:
- 26.
A chimeric anti-EMAPII antibody, comprising:
- a light-chain variable domain having an amino acid sequence set forth in SEQ ID NO:
- 11;
- and
- a heavy-chain variable domain set forth in SEQ ID NO:
- 19.
Dependencies are inferred from the claim text.